FA
ANGO icon

Friess Associates’s AngioDynamics ANGO Stock Holding History

Friess Associates’s Portfolio ANGO Stock Details ANGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-47,400
Closed -$650K – 144
2014
Q3 		$650K Buy
47,400
+9,400
+25% +$134K 0.06% 84
2014
Q2 		$621K Buy
+38,000
New +$550K 0.05% 83
2014
Q1 		– Sell
-40,000
Closed -$686K – 149
2013
Q4 		$686K Buy
+40,000
New +$616K 0.05% 79

Other funds holding ANGO

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Friess Associates's ANGO Position: Q4 2014 in Review

Friess Associates sold out of AngioDynamics (ANGO) in Q4 2014, closing a stake of 47,400 shares — an estimated $650K sold.

Friess Associates first reported a position in ANGO in Q4 2013 and held it in 3 quarters. The position peaked at $686K in Q4 2013. 132 funds tracked by Wall St. Rank hold ANGO as of Q4 2014.

  • Friess Associates reported no remaining AngioDynamics position as of Q4 2014 after selling out during the quarter.
  • Friess Associates sold 47,400 AngioDynamics shares in Q4 2014, an estimated $650K.
  • Friess Associates first reported a position in AngioDynamics in Q4 2013 and held it in 3 quarters.
  • Friess Associates's AngioDynamics position peaked at $686K in Q4 2013.
  • 132 funds tracked by Wall St. Rank held AngioDynamics as of Q4 2014.

Based on Friess Associates's 13F filing for Q4 2014, filed 13 Feb 2015.